International Journal of Clinical Science and Medical Research

Back Ground: The incidence of many infections is higher in elders, and these individuals are more prone to severe infections due to immunosenescense combined with progressive increase of proinflammatory status (inflammaging) which enhances susceptibility to morbidity, mortality and hospitalization. 

Pneumococcal disease, influenza and HZV infections are known to cause high morbidity and mortality in older adults. 

Objective: Aim of this study was to know prevalence of vaccination for Pneumococcal, influenza and HZV vaccines and associated comorbidities in elderly adults. 

Method. This is cross section study of 1894 patients’ elderly adults ages 65 and above from Hatta hospital registry for vaccination statuses of pneumococcal, Influenza and HZV vaccines. Associated comorbid conditions DM, heart disease, COPD, CKD, Dyslipidemia and cancer were noted.   

Results: A total of 1894 patients were included in the study and analyzed. Male 1013 (53.5%), Female 881 (46.5%). 52% UAE nationals, 16.5% Omani and 31.5% were from other nationalities. 

Over all 892 (47.2%) patients have comorbidities. Among chronic diseases 33% (626) had DM, 28.2% (535) heart diseases, 6.7% (127) CKD, 1.3% (24) COPD, 146 (7.7%) Dyslipidemia and 2.5% (48) had cancer. 

Out of total, 232 (12.2%) had influenza vaccine, 84 (4.4%) pneumococcal and 34 (1.8%) got HZV vaccine. p-value was significant (<0.05) for pneumococcal, influenza and HZV vaccine with overall comorbidities and different individual comorbidities. 

Conclusion: Vaccination coverage among elderly in our study was low. Most received was flu vaccine 12.2 % followed by 4.4% for pneumococcal vaccine < 2% for HZV. This highlights the need to take steps to overcome the vaccine hesitancy and increase the vaccination in elderly population.

Elder adult, Pneumococcal vaccination, Influenza vaccination, HZV, comorbidity

1. He, W.; Goodkind, D.; Kowal, P. An Aging World; United States Census Bureau: Washington, DC, USA, 2015 
2. Eurostat. Population structure and aging. (2021) Available at: https://ec. europa.eu/eurostat/statistics-explained/index.php?title=Population_ structure_and_ageing. Accessed 18 July 2021. 
3. Gavazzi G, Krause K. Ageing and infection. Lancet. 2002;2:659–66. https://doi. org/10.1016/S1473-3099(02)00437-1. 
4. Kline, K.A.; Bowdish, D.M.E. Infection in an aging population. Curr. Opin. Microbiol. 2016, 29, 63–67. 
5. Aw, D.; Silva, A.B.; Palmer, D.B. Immunosenescence: Emerging challenges for an ageing population. Immunology 2007, 120, 435–446. 
6. Aiello, A.; Farzaneh, F.; Candore, G.; Caruso, C.; Davinelli, S.; Gambino, C.M.; Ligotti, M.E.; Zareian, N.; Accardi, G. Immunose nescence and its hallmarks: How to oppose aging strategically? A review of potential options for therapeutic intervention. Front. Immunol. 2019, 10, 2247. 
7. Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges of pneumococcal disease in adults. Eur Resp Rev 2012;21(123):57–65. https:// doi.org/10.1183/09059180.00008911 
8. Centres for Disease Control and Prevention. Pneumococcal disease (Streptococcus pneumoniae); 2014. Available from: [April 11, 2018]. 
9. McLaughlin JM, McGinnis JJ, Tan L, Mercatante A, Fortuna J. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Primary Prevent 2015;36(4):259–73 
10. Pneumokokkener krankungen 2012 [Pneumococcal Disease 2012]. Swiss Federal Office of Public Health (2014).
11. Pneumokokkenr Erkrankungen [Pneumococcal Illnesses]. Krankheiten A-Z [Diseases A-Z]. Bern: Swiss Federal Office for Public Health (2021). 
12. Pneumococcal vaccines (PCV13 and PPSV23): addressing common questions about pneumococcal vaccination for adults. Atlanta: United States Centers for Disease Control and Prevention; 2019. Available from: https:// www .cdc .gov/ pneumococcal/ resources/ prevent -pneumococcal -factsheet .pdf [cited 2021 May 21]. 
13. Centers for Disease Control and Prevention. Surveillance and reporting; 2017. Available from: [March 27, 2018] 
14. World Health Organization, Up to 650 000 People Die of Respiratory Diseases Linked to Seasonal Flu Each Year, World Health Organization, 2017 (Accessed July 31, 2018), http://www.who.int/news-room/detail/14-12-2017-up-to-650 000-people-dieof-respiratory-diseases-linked-to-seasonal-flu-each-year. 
15. Uyeki, T.M.; Hui, D.S.; Zambon, M.; Wentworth, D.E.; Monto, A.S. Influenza. Lancet 2022, 400, 693–706 
16. Macias, A.E.; McElhaney, J.E.; Chaves, S.S.; Nealon, J.; Nunes, M.C.; Samson, S.I.; Seet, B.T.; Weinke, T.; Yu, H. The disease burden of influenza beyond respiratory illness. Vaccine 2021, 39, A6–A14. 
17. Australian Institute of Health and Welfare. The Burden of Vaccine Preventable Diseases in Australia; Australian Institute of Health and Welfare: Canberra, Australia, 2019; 
18. Kline, K.A.; Bowdish, D.M.E. Infection in an aging population. Curr. Opin. Microbiol. 2016, 29, 63–67. 
19. Cunningham, A.L.; McIntyre, P.; Subbarao, K.; Booy, R.; Levin, M.J. Vaccines for older adults. BMJ 2021, 372, n188. 
20. Centers for Disease Control and Prevention. Ten great public health achievements– worldwide, 2001–2010. MMWR Morb Mortal Wkly Rep. 2011; 60:814–8. 
21. Global vaccine action plan 2011–2020. Geneva: World Health Organization; 2012. Available from: https:// www. who .int/ publications/ i/ item/ global -vaccine -action plan -2011 -2020 
22. Immunization agenda 2030: a global strategy to leave no one behind. Geneva: World Health Organization; 2020. Available from: https:// www .who .int/ publications/ m/ item/ immunization -agenda -2030 -a -global -strategy to leave no one -behind [cited 2021 Jun 5]. 
23. Vaccination coverage among older adults: a population-based study in India, Ali Abbas Rizvi , Abhishek Singh; https://www.researchgate.net/publication/361283806_Vaccination_coverage_among_ older adults, a population-based study in India. 
24. Fan J, Cong S, Wang N, Bao H, Wang B, Feng Y, et al. Influenza vaccination rate and its association with chronic diseases in China: results of a national cross-sectional study. Vaccine. 2020 Mar 4;38(11):2503–11. doi: http:// dx .doi .org/ 10 .1016/ j. vaccine .2020 .01 .093 PMID: 32046892 
25. Erbay A, Kader Ç, Ede H, et al. [Influenza and pneumococcal vaccination uptake in adults aged ≥65 years and high-risk groups admitted to Yozgat Bozok University Research and Application Hospital].  Klimik Derg. 2018; 31(3): 205-9. Turkish 
26. Study to increase the pneumococcal vaccination rates of in aged 65 years and older  M V Biyik , I Arslan , D Yengil; Taci pmc.ncbi.nlm.nih.gov/articles/PMC7576541 
27. Wyplosz B, Fernandes J, Goussiaume G, Moïsi J, Lortet-Tieulent J, Vainchtock A, et al. Adults at risk of pneumococcal disease in France. Infect Dis Now. (2021) 51:661–6. doi: 10.1016/j.idnow.2021.07.006 
28. FH.C.f. Health P. Infections à Pneumocoque: Recommandations Vaccinales Pour les Adultes [Pneumococcal Infections: Vaccine Recommendations for Adults] (2017). 
29. Kopp A, Mangin O, Gantzer L, Lekens B, Simoneau G, Ravelomanantsoa M, et al. Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease. Hum Vaccines Immunother. (2021) 17:162–9. doi: 10.1080/21645515.2020.1756669